Wilms’ tumor protein and FLT3‐internal tandem duplication expression in patients with de novo acute myeloid leukemia

Figures & data

Table 1. Patients characteristics

Patients
n	30
Age (n = 30) (years)
Median	48
Range	27–59
AML patients <60 years	30
Gender – no. of patients (%)
Male	20	(66·7)
Female	10	(33·3)
De novo AML	30
WBC count (×10^9/l)
Median	19·5
Range	1·7–337
Hemoglobin level (g/l)
Median	95
Range	50–140
PLT count (×10^9/l)
Median	60
Range	5–264
WHO subtype – no. of patients (%)
AML with recurrent cytogenetic translocations	9	(30)
AML with multilineage dysplasia – without prior MDS	2	(6·7)
AML not otherwise categorized	19	(63·3)
Cytogenetic risk group – no. of patients
Low [t(8;21/AML1‐ETO n = 5; inv(16)/CBFB‐MYH11 n = 4)]	9
Intermediate risk (normal karyotype n = 13)	13
High risk (complex karyotype n = 2)	2
No metaphases available*	6

Note: *RT‐PCR for AML1‐ETO, CBFb‐MYH11, PML‐RARa, and BCR‐ABL was performed and tested negative in all patients.

Figure 1. Western blot detection of Wt1 expression (52 kDa). p: positive control (cell line K‐562); n: negative control (cell line U‐937); lane 1–6: samples from AML patients. Semiquantitative probe evaluation: samples 1, 2, and 4 are negative (−), samples 5 and 6 are weekly positive (+) and sample 3 is strongly positive (+++).

Figure 2. RT‐PCR detection of FLT3‐ITD.

Table 2. Correlation of Wt1 with common cytogenetic aberrations in AML patients

	Total	No Wt1		Low Wt1		High Wt1
		n (%)		n (%)		n (%)
AML total	30	14	(46·7%)	7	(23·3%)	9	(30%)
Cytogenetics (n = 24)	24
Normal karyotype		5	(38·5%)	3	(23%)	5	(38·5%)
t(8;21)/AML1‐ETO and inv(16)/CBFB‐MYH11		6	(66·7%)	3	(33·3%)	…
Other karyotypes				1	(50%)	1	(50%)

Table 3. Correlation of FLT3‐ITD with common cytogenetic aberrations in AML patients

	Total	No FLT3‐ITD		FLT3‐ITD
		n (%)		n (%)
AML total	30	23	(76·7%)	7	(23·3%)
Cytogenetics (n = 24)	24
Normal karyotype		8	(61·5%)	5	(38·5%)
t(8;21)/AML1‐ETO and inv(16)/CBFB‐MYH11		9	(100%)	…	…
Other karyotypes		2	(100%)	…	…

Figure 3. Co‐expression of Wt1 protein and FLT3‐ITD in de novo AML patients.

Figure 4. Overall survival of all de novo diagnosed AML patients according Kaplan‐Meier calculation in relation to FLT3‐ITD expression [no FLT3‐ITD (−) versus FLT3‐ITD (+)].